The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.

Tagrisso, Imfinzi, Truqap, and Enhertu all reported double-digit sales growth during the fourth quarter and full-year 2025 ...

The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at ...

Gilead's other CAR-T therapies also performed poorly over the same period. In Q5 2025, Yescarta sold $368 million, down 6 ...

Ultragenyx recently resubmitted a BLA seeking approval for the gene therapy after the FDA rejected it, and the firm will resubmit it again in response to new questions.

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat ...

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology ...

Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 ...

The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion ...

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi ...

Researchers are evaluating Lyell's CD19/20 dual-targeting CAR-T against marketed CD19 CAR T-cell therapies in the second-line refractory large B-cell lymphoma setting.

Vertex posted revenue and earnings for Q4 and full-year 2025 that hovered around consensus Wall Street estimates, but CRISPR Therapeutics missed expectations.